Erasca, Inc.
Every calculator, already run for ERAS
Open the full toolkit →You have the numbers on ERAS. Get the argument.
A written report on which of these readings actually decide the outcome for Erasca, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering ERASOwnership & short interest
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develo…
ERAS — frequently asked
Is ERAS a buy right now?
Wall Street's consensus rating on Erasca, Inc. is none across 10 analysts, with a mean price target of $22.80 (+22% vs. the current $18.68). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ERAS's next earnings date?
Erasca, Inc. is next scheduled to report earnings around Aug 12, 2026. A full ERAS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
Compare Erasca, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Erasca, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ERAS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Erasca, Inc., in minutes. 3 free reports included with every account — no credit card required.